## (TRANSLATION OF THE OFFICIAL FILE)

Faculty of Medicine, University of Belgrade

Ethics Committee Number: 1322/IX-40 Date: 29.9.2022.

In accordance with the Art. 146. of the Statute of the Faculty of Medicine, University of Belgrade, and the Art. 3. of the Regulatory Book on the Work of the Ethics Commission of the Faculty of Medicine, University of Belgrade, upon request of prof. dr Mirjana Šumarac Dumanović on giving consent on the conduction of the clinical study "Effect of sulforaphane supplementation on hematological and serum parameters related to ferroptosis in type 1 diabetic patients", the Ethics Committee of the Faculty of Medicine, University of Belgrade has made a following decision on September 29 of 2022:

## **DECISION**

The consent on the conduction of the clinical study "Effect of sulforaphane supplementation on hematological and serum parameters related to ferroptosis in type 1 diabetic patients", has been given to prof. Dr Mirjana Šumarac Dumanović, Clinic of Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Belgrade.

The appointee undertakes to keep the data on the study participants for at least ten years, and to absolutely protect the identity data of the participants, in accordance with the Law on data protection of Republic of Serbia.

## Rationale

Prof. dr Mirjana Šumarac Dumanović, has submitted an application to the Ethics Commission in order to provide a consent on the conduction of the clinical study "Effect of sulforaphane supplementation on hematological and serum parameters related to ferroptosis in type 1 diabetic patients". The study will be accomplished in the Clinic of Endocrinology, diabetes and metabolic diseases, University Clinical Center of Serbia, Belgrade in the with the Institute for Biological Research "Siniša Stanković" – National Institute of the Republic Serbia, University of Belgrade and the Faculty of Biology, University of Belgrade, as a part of the proposed project "Targeting ferroptosis in diabetes and diabetic complications by hydrogen (per)sulfide" (DiaSulFer), program PRISMA of the Science Fund of Republic of Serbia.

After reviewing the mentioned application, in accordance with the conditions prescribed in the Regulatory Book on the Work of the Ethics Commission of the Faculty of Medicine, University of Belgrade, the given decision has been made.

Signed by:

Prof. dr Siniša Pavlović President of the Ethics Committee Faculty of Medicine, University of Belgrade